All In Biotech

Drug Trial Radar · NCT07662109

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Jul 6, 2026

Primary completion

Jul 5, 2028

Study completion Jul 5, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • ElecoglipronDrug

    Elecoglipron is administered orally once daily.

  • DapagliflozinDrug

    Dapagliflozin administered orally once daily.

  • Elecoglipron-matched placeboDrug

    A placebo matching elecoglipron administered orally once daily.

  • Dapagliflozin-matched placeboDrug

    A placebo matching dapagliflozin administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline to Week 40

Locations

303 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama · Not yet recruiting

  • Research Site

    Mobile, Alabama · Not yet recruiting

  • Research Site

    Sheffield, Alabama · Not yet recruiting

  • Research Site

    Little Rock, Arkansas · Recruiting

  • Research Site

    Bakersfield, California · Not yet recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Ontario, California · Not yet recruiting

  • Research Site

    Lake City, Florida · Recruiting

  • Research Site

    Lakeland, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Not yet recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Skokie, Illinois · Not yet recruiting

  • Research Site

    Evansville, Indiana · Not yet recruiting

  • Research Site

    Sioux City, Iowa · Not yet recruiting

  • Research Site

    Zachary, Louisiana · Not yet recruiting

  • Research Site

    Annapolis, Maryland · Not yet recruiting

  • Research Site

    Lutherville-Timonium, Maryland · Not yet recruiting

  • Research Site

    Oxon Hill, Maryland · Recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    Troy, Michigan · Recruiting

  • Research Site

    Ridgeland, Mississippi · Recruiting

  • Research Site

    Elkhorn, Nebraska · Not yet recruiting

  • Research Site

    Toms River, New Jersey · Not yet recruiting

  • Research Site

    Albuquerque, New Mexico · Recruiting

  • Research Site

    Brooklyn, New York · Recruiting

  • Research Site

    Rosedale, New York · Not yet recruiting

  • Research Site

    Raleigh, North Carolina · Not yet recruiting

  • Research Site

    Beachwood, Ohio · Not yet recruiting

  • Research Site

    Maumee, Ohio · Recruiting

  • Research Site

    Norman, Oklahoma · Not yet recruiting

  • Research Site

    Philadelphia, Pennsylvania · Not yet recruiting

  • Research Site

    Kingsport, Tennessee · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Dallas, Texas · Recruiting

  • Research Site

    McKinney, Texas · Not yet recruiting

  • Research Site

    Paris, Texas · Recruiting

  • Research Site

    San Antonio, Texas · Not yet recruiting

  • Research Site

    Webster, Texas · Withdrawn

  • Research Site

    Layton, Utah · Not yet recruiting

Showing 40 of 303 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.